PHVS (pharvaris.com) מזומני החברה

Pharvaris N.V. is making a breakthrough by replacing painful injections for HAE swelling with convenient tablets. The cash balance on the GURU.Markets service confirms liquidity dynamics, where 0.32 determines the current status of the parameter. Despite a revenue deficit and the depletion of reserves for R&D, the company possesses significant pricing power due to the uniqueness of the drug and inelastic patient demand.
פילוחים אנליטיים ודוחות נתונים של חברת Pharvaris NV (PHVS)

This metric measures the volume of liquid assets, determining the business's ability to fund operating activities and R&D without incurring debt. By analyzing the cash position on GURU.Markets, an investor can assess the resource reserves of Pharvaris N.V. (PHVS) for completing deucavacib trials and engaging with the FDA, which is critical for the biopharmaceutical sector while awaiting strategic partnerships.